SCHEMBL4294864

SCHEMBL4294864

c1ccc(-c2ccncn2)nc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.67
LMNA P02545 3/20 0.67
CCR1 P32246 3/20 0.67
CCR5 P51681 3/20 0.67
CCR8 P51685 3/20 0.67
METAP1 P53582 2/20 0.67
CYP1A2 P05177 1/20 0.67
POLB P06746 1/20 0.67
BLM P54132 1/20 0.67
HIF1A Q16665 1/20 0.67
DOHH Q9BU89 1/20 0.67
P4HTM Q9NXG6 1/20 0.67
NPC1 O15118 6/20 0.56
RAB9A P51151 5/20 0.56
TP53 P04637 4/20 0.56
ALOX15 P16050 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
HTT P42858 2/20 0.56
TDP1 Q9NUW8 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394083 1.00 KDM4E (0.67) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL27634628 0.85 KDM4E (0.74) KDM4ELMNACCR1CCR5CCR8
SCHEMBL10402322 0.85 HSP90AA1 (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL30595872 0.84 HSP90AA1 (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL2814353 0.84 HSP90AA1 (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1181563 0.82 KDM4E (0.88) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL29351528 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL29907716 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL3711450 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8
Dipyridyl SCHEMBL5922 0.82 KDM4E (1.00) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107434801-B 4 '-pyridyl-pyrimidine class compounds of one kind and its synthetic method and application 南京林业大学 2019-08-27 CN claimed
CN-107434801-A A kind of 4 ' pyridyl-pyrimidine class compounds and its synthetic method and application 南京林业大学 2017-12-05 CN claimed
EP-4504985-A1 METHOD FOR HIGH AND SELECTIVE EXTRACTION OF A PRECIOUS METAL Singapore Polytechnic (SG) 2025-02-12 EP disclosed
CN-118922566-A Method for extracting noble metal with high selectivity 新加坡理工学院 2024-11-08 CN disclosed
WO-2023191722-A1 METHOD FOR HIGH AND SELECTIVE EXTRACTION OF A PRECIOUS METAL SINGAPORE POLYTECHNIC (SG) 2023-10-05 WO disclosed
EP-4225310-A1 HETEROARYL AMIDE INHIBITORS OF CD38 Napa Therapeutics Ltd. (VG) 2023-08-16 EP disclosed
US-11673100-B2 Systems and methods for integrated solar photodialysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-13 US disclosed
US-11678498-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-13 US disclosed
US-11673100-B2 Systems and methods for integrated solar photodialysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-13 US disclosed
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. 2022-10-20 US disclosed
WO-2022119501-A1 METHOD FOR HIGH AND SELECTIVE EXTRACTION OF SILVER SINGAPORE POLYTECHNIC (SG) 2022-06-09 WO disclosed
WO-2006072426-A1 ALKINYL-OXYPYRIMIDINE USED IN THE FORM OF PESTICIDES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2006-07-13 WO disclosed
EP-1608375-A1 METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK Signal Pharmaceuticals LLC (US) 2005-12-28 EP disclosed
WO-2004084901-A1 METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK SIGNAL PHARMACEUTICALS, LLC (US) 2004-10-07 WO disclosed
US-20040106634-A1 Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-06-03 US disclosed
CN-1246856-A Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents AMGEN INC (US) 2000-03-08 CN disclosed
US-5304647-A Addition of an organolithium reagent; dehydrogenation of addition product; two-phase conditions prevents hydrolysis GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1994-04-19 US disclosed
US-4963676-A INTERMEDIATES FOR NOVEL UNFUSED HETEROBICYCLIC COMPOUNDS WITH BIOLOGICAL ACTIVITY; ANTICANCER AGENTS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1990-10-16 US disclosed
US-4929726-A ANTICARCINOGENIC AGENTS GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1990-05-29 US disclosed
WO-1989007599-A2 NOVEL DIAZINES AND THEIR METHOD OF PREPARATION GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) 1989-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106634-A1 Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK MAPK6, MAPKAPK2, DUSP6 KDM4E 3645/4885LMNA 3512/4885CCR1 1075/4885
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYP46A1, CYP26A1, CYP21A2 KDM4E 2676/4885LMNA 2357/4885CCR1 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.